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Introduction: Prostacyclin (PG) remains the gold standard therapy for severe pulmonary arte-
rial hypertension (PAH). Previously, we reported the successful transitioning of PAH subjects
from intravenous prostacyclin to oral bosentan (Suleman et al. Chest 2004;126:808e15). We
report here the 5-year follow-up data.
Methods: In the transition study, 11 PAH subjects were successfully transitioned to oral bosen-
tan in 12 weeks. Two subjects who subsequently developed liver function test (LFT) abnormal-
ities were taken off bosentan and switched to another endothelin receptor antagonist.
Demographics, six-minute walk distance (6MWD), WHO functional class (FC), and survival data
was collected.
Results: 10 Females and 1 male ranging in age from 35 to 79 were successfully transitioned.
Mean duration of illness prior to transition was 50.55 26 months. Mean duration that these
subjects remained on oral therapy was 34 24 months. Mean duration that patients remained
off PG was 28  21 months. In 7 of the 11 subjects (64%), PG was resumed due to clinical
deterioration. One patient remained on bosentan as monotherapy, five had phosphodiesterase
5-inhibitor added. 9 Of the 11 subjects were WHO FC II post-transition and 5 of the 7 subjects
at follow-up were WHO FC II (82% vs 67%). Post-transition 6MWD was 386 85 in 10 subjects and
at follow-up 6MWD was 396 99 in 9 subjects (pZ 0.81).
Conclusions: In this study, patients frequently required prostanoid resumption after transition
from intravenous prostanoid to oral therapy. However, in these carefully selected patients,
transition to oral therapy offered prolonged stable FC and 6MWD, cost savings and substantial
quality of life benefits.
ª 2009 Elsevier Ltd. All rights reserved.798 2688.
9 Elsevier Ltd. All rights reserved.
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Pulmonary arterial hypertension (PAH) is a progressive
disease that results from remodeling of pulmonary arteries
and leads to right heart failure.1,2 Intravenous prostacyclin
(PG) was the first FDA approved therapy to treat PAH.3
Subsequently, oral agents became available and several
papers indicated that carefully selected PAH patients could
be successfully transitioned from systemic prostanoids
(epoprostenol IV or treprostinil subcutaneously) to oral
agents such as an endothelin receptor antagonist (ERA) or
phosphodiesterase 5-inhibitor (PDE5-i).4e6
Although prostanoids remain the preferred treatment
for PAH patients with severe disease, this therapy has
socioeconomic and psychological impact on the patients. A
chronic indwelling catheter and the side-effect profile of
PG can influence the quality of life in these patients.
Various studies have shown that patients transitioned to
oral agent can maintained their stable functional status and
walk distance over a short period of time.4,6,7 However,
long-term follow-up data after the successful transition to
oral therapy is missing. This is important, as PAH is
a progressive disease and most patients require escalation
of therapies over time.8 In addition, with the FDA approval
of newer agents since the initial approval of epoprostenol,
offers an option to start patients on these agents.9e11 In
addition, availability of newer agents as part of a research
protocols may be an option for these patients.
We present our long-term data for up to 70 months on
eleven patients that were successfully transitioned from
continuous systemic prostanoids (treprostinil e TRE; or
epoprostenol e EPO) to oral bosentan in 2002e2003 in our
previously reported study.Methods
In the previous study, 11 PAH subjects were successfully
transitioned to oral bosentan in 12 weeks.4 Two PAH
subjects subsequently developed liver function abnormali-
ties and were switched to another ERA and nine were
continued on bosentan. Demographic, six-minute walkTable 1 Demographics of successful transitions.
Patient no. Gender Age, year Race
7 Female 50 Caucasian
8 Female 74 Caucasian
9 Female 79 Caucasian
10 Female 38 Caucasian
11 Female 51 Hispanic
12 Female 43 Caucasian
13 Male 47 Hispanic
17 Female 50 Africo-American
18 Female 65 Caucasian
22 Female 35 Africo-American
23 Female 62 Caucasian
Mean SD 54 14
IPAH, idiopathic pulmonary arterial hypertension; and CVD, collagendistance (6MWD), WHO functional class (FC), and long-term
data was obtained.
Immediate post-transition data and data at last clinic
follow-up were obtained. Except for the four patients that
relocated to other areas, the last date for the data
collection was August 2008. One patient relocated 5 months
after transition and therefore no data could be obtained
(patient 9), the remaining 3 patients relocated 2.5 years, 5
years and 7 years after the transition. Estimated pulmonary
artery systolic pressure and cardiac output were obtained
from an echocardiogram.
Statistical analysis: Data presented as mean SD.
p-value considered significant at 0.05.
Results
10 Females and 1 male that were successfully transitioned
to oral bosentan had ages ranging from 35 to 79 (Table 1).
Duration of illness at the time of transition ranged from 17
to 112 months. Mean duration that these subjects remained
on oral therapy (ERA and PDE5-i) was 34 24 months (range
3e70 months) (Table 2). Mean duration that patients
remained off PG was 28 21 months.
Prostacyclin therapy was resumed in seven of the eleven
subjects due to clinical deterioration (range 3e68 months).
The dose of the PG at the time of follow-up was similar to
the dose prior to transition (pZ 0.62). One patient
remained on bosentan monotherapy 70 months after
successful transition. One patient who was on bosentan
monotherapy relocated 5 months following transition and
died two years later at the age of 75. Four patients remain
off any prostacyclin therapy at the time of last clinic
follow-up. One patient was started on oral treprostinil (as
part of a research protocol). One patient who was started
on epoprostenol underwent successful lung transplantation
and following that was not on any PAH therapy. Five had
a PDE5-i added to their regimen.
9 Of the 11 subjects were WHO FC II post-transition and 6
of the 9 subjects at last follow-up were WHO FC II (82% vs
67%) (Fig. 4). Post-transition 6MWD was 386 85 in 10
subjects and at follow-up 6MWD was 396 99 in 9 subjects
(pZ 0.81) (Fig. 1). The six-minute walk distance wasEtiology of PAH Duration of illness at transition, months
IPAH 36
IPAH 17
CVD 58
IPAH 46
CVD 59
IPAH 60
IPAH 112
CVD 28
CVD 45
PAH (HIV) 27
CVD 68
50 25
vascular disease.
Table 2 Transition data and data at last follow-up.
Patient no. PG type PG dose at transition
(ng/kg/min)
PG resumed Current PG dose
(ng/kg/min)
Duration on oral
therapy, months
PDE5-i ERA
7a EPO 16 EPO 18 30 Yes No
8 EPO 18 None None 62 Yes Yes
9a,b EPO 26 NA NA 5þ NA Yes
10 EPO 33 None None 70 No Yes
11 EPO 40 TRE-o 7 68 No Yes
12a EPO 42 TRE-sc 60 9 No Yes
13 EPO 54 EPO 70 18 Yes Yes
17 TRE 18 EPO 14 33 No No
18a,b TRE 19 None None 37þ Yes No
22 EPO 10 EPO 16 35 Yes No
23 TRE 9 EPO Lung transplant 3 No No
Mean SD 26 15 31 27 34 24
PG, prostacyclin; EPO, epoprotenol; TRE-o, oral treprostinil; TRE-sc, subcutaneous treprostinil; PDE5-i, phosphodiesterase 5-inhibitor;
ERA, endothelin receptor antagonist; and NA, not available.
a Pt relocated.
b Patient died.
1690 Z. Safdarmaintained in 9 patients at the time of last follow-up. The
hemodynamic data was obtained from the echocardiogram
post-transition and compared with the echocardiogram at
last follow-up. There was no significant change over the0
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Figure 1 Six-minute walk distance post-transition and at last
follow-up. Six-minute walk distance (meters) after transition
to oral bosentan and at the time of last follow-up. Patient 8
refused the reinstatement of PG therapy. Patient 9 relocated
to another state 5 months after transitioning to oral bosentan
(11/20/2002) and later died (8/4/2004). Patient 7 relocated 5
years after transition and was on epoprostenol at that time.
Patient 12 relocated 4 years and 2 months after transition and
was on subcutaneous treprostinil. Patient 18 relocated 3 years
after the transition while on epoprostenol (6/23/2005) and
later died (9/19/2005).time of follow-up in right ventricular systolic pressures
(pZ 0.87) (Fig. 2) and cardiac output (pZ 0.29) (Fig. 3).
Discussion
Parenteral prostanoid remain the gold standard of therapy
for treating patients with severe PAH.12,13 We had previ-
ously reported the successful transition of eleven PAH
patients who were on PG to oral bosentan.4 At the time of
our original transition study, bosentan was the only FDA
approved ERA available in USA.14,15 In this one center study,
many patients resumed PG (64%) but had a prolonged
prostanoid free honeymoon period. In these patients six-
minute walk distance and functional class was unchanged.
PAH is a progressive disease that requires escalation of
therapy over time.8 In our study, 45% had a second oralTransition Follow-up
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Figure 2 Pulmonary artery systolic pressures: Post-transition
and at follow-up. Data missing in patient #9 who relocated 5
months after transition while on oral bosentan. Patient 8
refused the reinstatement of PG therapy.
23
4
5
6
7
8
Transition Follow-up
C
a
r
d
i
a
c
 
o
u
t
p
u
t
(
L
/
m
i
n
)
Patient 7
Patient 8
Patient 10
Patient 11
Patient 13
Patient 18
Patient 23
Figure 3 Post-transition and follow-up cardiac output. Data
obtained from an echocardiogram and was missing in 3
patients.
Pulmonary hypertension 1691agent added to their regimen. A second agent and some-
times a third agent was added to maintain clinical status in
PAH subjects. More than half of the patients were
continued on the ERA and three of the seven patients (43%)
that resumed PG were also started on a second oral agent.
These data suggest that it may be possible to maintain the
walk distance and functional status by adding a second
agent after resuming the PG. Most of the patients that
continued on oral therapy ultimately required combination
therapy e an as yet unproven treatment modality although
as demonstrated here a common clinical practice. Clinical
trials testing different combination of PAH drugs are0
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Figure 4 WHO functional class at transition and at follow-up.
Data obtained from the last clinic visit.underway to determine the efficacy and safety of the
combination therapies.
In a previous single center study by Diaz-Guzman et al.
15 of the 21 patients were successfully transitioned to oral
therapy and maintained on an oral agent 24 month after
transition.6 In this study, successfully transitioned patients
were older than those that failed transition. The success-
fully transitioned patients had longer duration of prosta-
noid therapy, though not significantly different. There were
no significant differences in 6MWD, BNP, or RVSP between
the groups. Moreover, the duration of weaning period was
similar, and the dose of PG was not different between the
two groups.
In the study by Suleman et al, although there was a trend
towards longer duration of PG therapy, higher doses of PG,
and higher PAPs by ECHO in patients that failed transition,
these were not statistically significant. In addition, there
was no difference in age or etiology of PAH between the
successfully and failed transitioned groups.
In the study by Steiner et al, successfully transitioned
patients had lower PG dose, and lower PA pressures as
compared to failed group.7 There was a trend towards better
WHO FC, 6MWD, and Borg Dyspnea score in the transitioned
patients at baseline. Johnson et al conducted a retrospec-
tive review of 13 patients that were transitioned to oral
bosentan or sildenafil from intravenous epoprostenol.5 The
mean dose of PG before weaning was 23 ng/kg/min, similar
to the mean dose reported by Steiner, and Suleman et al.7,4
Three patients were re-started back on prostacyclin and
nine patients remained on an oral agent (69%).5
In all these studies, patients that were considered for
transitioning to oral therapy had to meet certain criteria for
disease stability. The two criteria that were considered
important in each of these studies were (1) infrequent or no
change in PG dose and (2) no evidence of right heart
failure. The mean duration of weaning period was 3, 4.5, 6
and 11 months in the studies by Suleman, Steiner, Johnson
and Diaz-Guzman respectively.4e7 Given the small number
of patients that were transitioned, data on duration of PG
therapy, 6MWD and hemodynamic is difficult to interpret.
In our study, patients were continued on bosentan as
monotherapy for a mean duration of 25 months and on
combination oral therapy for a mean duration of 34 months
excluding oral prostacyclin. Many patients (57%) remained
stable for substantial period of time on an oral agent.
In the study by Steiner et al 22 patients were identified
from 5 PH centers and ten were successfully transitioned to
oral bosentan.7 Seven of these ten patients (70%) were
maintained on oral therapy after a mean follow-up of 17.7
months with stable walk distance, WHO functional class,
and PA systolic pressures. This is in line with our observa-
tion where most patients that were re-started on a prosta-
cyclin therapy maintained stable clinical status with
unchanged functional status and walk distance.
In our study, none of the patients died immediately after
transitioning to an oral agent. Two patients on an ERA
relocated, and later died. One patient had PDE5-i added
prior to relocation. No deaths could be attributable to the
transition. Two patients that developed liver function
abnormalities were taken off bosentan. After the normali-
zation of their liver function test they were switched to
another oral ERA as part of a research protocol. Another
1692 Z. Safdarpatient who was on oral therapy for 68 months was started
on oral PG as part of a research protocol while being
continued on the ERA. These options were not available to
treat these patients when they were initially transitioned
to oral bosentan.
Intravenous PG though life-saving therapy for severe PAH
patients involves an indwelling catheter with continuous
infusions. Oral agents can provide a prolonged, safe and
beneficial period without the risk of line infection, pain,
prostanoid side-effects and limitation to quality of life
imposed by parenteral drug administration. The option to
transition patients that are on stable PG is an attractive
one. These patients had other therapies added during the
course of their illness. Although majority of the patients
were resumed on PG, walk distance, functional status, and
hemodynamics were maintained. Carefully selected
patients can be transitioned to oral therapy while main-
taining their walk distance and functional status. In these
patients, resuming PG does not result in decline of their
clinical status. These results suggest that transition to oral
therapy may be a viable option in carefully selected
patients and that these patients could maintain stable
clinical status while enjoying a prolonged prostanoid free
honeymoon period.
Conflict of interest statement
Dr Safdar is on the Scientific Advisory Board and Speaker for
Gilead Sciences, Actelion and United Therapeutics.
Acknowledgments
The author wishes to thank Dr Adaani Frost, Helena Purl and
Salman Ahmed for their help in the preparation of this
manuscript.
References
1. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of
pulmonary arterial hypertension: ACCP evidence-based clinical
practice guidelines. Chest 2004;126:78Se92S.
2. Hoshikawa Y, Voelkel NF, Gesell TL, et al. Prostacyclin
receptor-dependent modulation of pulmonary vascular
remodeling. Am J Respir Crit Care Med 2001;164:314e8.3. Badesch DB, McLaughlin VV, Delcroix M, et al. Prostanoid
therapy for pulmonary arterial hypertension. J Am Coll Cardiol
2004;43:56Se61S.
4. Suleman N, Frost AE. Transition from epoprostenol and tre-
prostinil to the oral endothelin receptor antagonist bosentan
in patients with pulmonary hypertension. Chest 2004;126:
808e15.
5. Johnson RF, Loyd JE, Mullican AL, et al. Long-term follow-up
after conversion from intravenous epoprostenol to oral
therapy with bosentan or sildenafil in 13 patients with
pulmonary arterial hypertension. J Heart Lung Transplant
2007;26:363e9.
6. Diaz-Guzman E, Heresi GA, Dweik RA, et al. Long-term
experience after transition from parenteral prostanoids to oral
agents in patients with pulmonary hypertension. Respir Med
2008;102:681e9.
7. Steiner MK, Preston IR, Klinger JR, et al. Conversion to
bosentan from prostacyclin infusion therapy in pulmonary
arterial hypertension: a pilot study. Chest 2006;130:1471e80.
8. Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to
long-term intravenous epoprostenol therapy in patients with
pulmonary arterial hypertension: a randomized trial. Ann
Intern Med 2008;149:521e30.
9. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate
therapy for pulmonary arterial hypertension. N Engl J Med
2005;353:2148e57.
10. Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the
treatment of pulmonary arterial hypertension: results of the
ambrisentan in pulmonary arterial hypertension, randomized,
double-blind, placebo-controlled, multicenter, efficacy
(ARIES) study 1 and 2. Circulation 2008;117:3010e9.
11. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost
for severe pulmonary hypertension. N Engl J Med 2002;347:
322e9.
12. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous
intravenous epoprostenol (prostacyclin) with conventional
therapy for primary pulmonary hypertension. The Primary
Pulmonary Hypertension Study Group. N Engl J Med 1996;334:
296e302.
13. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary
pulmonary hypertension with long-term continuous intrave-
nous prostacyclin. Ann Intern Med 1994;121:409e15.
14. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for
pulmonary arterial hypertension. N Engl J Med 2002;346:
896e903.
15. Channick R, Badesch DB, Tapson VF, et al. Effects of the dual
endothelin receptor antagonist bosentan in patients with
pulmonary hypertension: a placebo-controlled study. J Heart
Lung Transplant 2001;20:262e3.
